Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Insider trades › Alterity Therapeutics › CEO reported a non-open-market transaction in ATHE
Derivative units · @ $0.50
Why it stands out Not classified as an open-market trade.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Transaction date Aug 31, 2026
Reporting period Not applicable
Filed with the SEC Sep 9, 2026 CEO Other
Context Classification other
Code P in the derivative table; not an open-market share purchase
Planned / mechanical clue None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID 0002130205-26-000002
Filed / recorded
Sep 9, 2026, 2:52 AM UTC
Added to OQRO Oct 8, 2026, 9:25 PM UTC
Data quality Verified: identifiers matched exactly
Issuer ALTERITY THERAPEUTICS LTD
Reporting person David Allen Stamler
Relationship Director, Officer
Officer title Chief Executive Officer
Security Listed option exp 31 Aug 2026
Table Derivative (Table II)
Transaction date Aug 31, 2026
Acquired / disposed Disposed (D)
Around the same time Insider buying
Traded Aug 31 · filed 9 days later
An Alterity Therapeutics director paid $24K out of pocket for Alterity Therapeutics shares. Shares held went up 33% with this purchase.
Insider filing
Traded Aug 31 · filed 9 days later
Not classified as an open-market trade.
Insider filing
Traded Jun 15 · filed 9 days later
Compensation award — excluded from discretionary-purchase analysis.
